The phase 3 TILVANCE-301 trial (NCT05727904) evaluating the tumor infiltrating lymphocyte (TIL) therapy, lifileucel (LN-144) in combination with pembrolizumab (Keytruda) vs pembrolizumab alone has randomized its first patient with frontline advanced, unresectable, or metastatic melanoma.
Clinical Trials
First-Line Nivolumab/Ipilimumab Followed by Nivolumab in a Clinically Diverse Population With Unresectable Stage III or IV Melanoma
In the phase IIIb CheckMate 401 trial reported in the Journal of Clinical Oncology, Reinhard Dummer, MD, and colleagues described outcomes with first-line nivolumab/ipilimumab followed by nivolumab in a clinically diverse population of patients with unresectable stage III or IV melanoma, including patients with a poorer performance status, brain metastases, and different melanoma subtypes.
Data Support Adjuvant Pembrolizumab as Standard Care in Stage IIB/C Melanoma
Adjuvant pembrolizumab provides a continued benefit for patients with stage IIB or IIC melanoma at 3 years, according to research presented at the ASCO Annual Meeting 2023.
Personalized mRNA Vaccine Reduces Risk of Melanoma Spread
A customized messenger RNA (mRNA) cancer vaccine being developed by Moderna and Merck plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk for metastasis in people with high-risk advanced melanoma, according to updated study results presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.